Autolus Therapeutics PLC Sponsored ADR (AUTL) – What Are Investment Firms Thinking About This Stock?

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) have earned an average recommendation of “Moderate Buy” from the seven research firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $10.00.

AUTL has been the topic of several research reports. Weiss Ratings raised shares of Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. Wall Street Zen upgraded shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, August 16th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research note on Monday, August 3rd.

Autolus Therapeutics Stock Down 2.4%

AUTL stock opened at $1.62 on Thursday. Autolus Therapeutics has a twelve month low of $1.18 and a twelve month high of $2.58. The company has a quick ratio of 4.40, a current ratio of 4.89 and a debt-to-equity ratio of 1.04. The firm has a market capitalization of $431.18 million, a PE ratio of -1.53 and a beta of 2.15. The stock has a 50-day simple moving average of $2.01 and a two-hundred day simple moving average of $1.75.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.06. Autolus Therapeutics had a negative net margin of 238.66% and a negative return on equity of 178.66%. The firm had revenue of $45.69 million for the quarter, compared to analysts’ expectations of $38.56 million. On average, equities analysts predict that Autolus Therapeutics will post -0.76 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. QRG Capital Management Inc. lifted its stake in shares of Autolus Therapeutics by 67.7% in the second quarter. QRG Capital Management Inc. now owns 18,325 shares of the company’s stock worth $29,000 after buying an additional 7,400 shares in the last quarter. Alphabet Inc. bought a new stake in Autolus Therapeutics in the 2nd quarter worth approximately $1,117,000. Syncona Portfolio Ltd purchased a new stake in Autolus Therapeutics during the 2nd quarter valued at $26,625,152. Hennion & Walsh Asset Management Inc. boosted its stake in shares of Autolus Therapeutics by 2.5% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 451,403 shares of the company’s stock worth $722,000 after buying an additional 11,197 shares during the last quarter. Finally, GAMMA Investing LLC increased its position in Autolus Therapeutics by 115.6% during the second quarter. GAMMA Investing LLC now owns 15,499 shares of the company’s stock valued at $25,000 after acquiring an additional 8,309 shares during the last quarter. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing programmed T-cell therapies for the treatment of cancer. The company’s platform is designed to genetically engineer T cells so they can recognize cancer targets, remain active in the body, and potentially reduce some limitations associated with conventional cell therapies.

Its lead product, obecabtagene autoleucel, is an autologous CAR T-cell therapy marketed in the United States as Aucatzyl.